. 2008 Apr 28;52(7):2313–2323. doi: 10.1128/AAC.01649-07

TABLE 2.

Effects of CBR-2092 and comparator agents on the in vitro activity of target enzymes from S. aureus

Test agent	IC₅₀ (μM) forσ^A RNA polymerase		CC₅₀ (μM) for:				CC₅₀ ratio for type II DNA topoisomerases
	Rif^s (RpoB^WT)^a	Rif^r (RpoB^H481Y)	DNA topoisomerase IV		DNA gyrase		GyrA^WT/ParC^WT	ParC^S80F/ParC^WT
	Rif^s (RpoB^WT)^a	Rif^r (RpoB^H481Y)	ParC^WT	ParC^S80F	GyrA^WT	GyrA^S84LParC^WT	GyrA^WT/ParC^WT	ParC^S80F/ParC^WT
CBR-2092	0.034	>25	1.7	2.7	1.5	>150	0.9	1.6
Rifampin	0.015	>25	NR^b	NR	NR	NR	NR	NR
Ciprofloxacin	NR	NR	0.4	31	4.6	>150	11.5	77.5
Gatifloxacin	NR	NR	0.22	13	0.7	18	3.2	59.1
ABT-719	NR	NR	0.06	1.1	0.09	0.9	1.5	18.3

WT, wild type.

NR, not relevant.